Break-point Checkerboard Plate' for screening of appropriate antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa

Scandinavian Journal of Infectious Diseases

Volumn 38, Issue 4, 2006, Pages 268-272

  Tateda, Kazuhiro ^a   Ishii, Yoshikazu ^a   Matsumoto, Tetsuya ^a   Yamaguchi, Keizo ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; PIPERACILLIN; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG POTENTIATION; MICROTITER PLATE ASSAY; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; SENSITIVITY ANALYSIS;

ANTI-BACTERIAL AGENTS; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA;

EID: 33744818934     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540500440353     Document Type: Article

References (29)

1. Livermore, DM. (2002) Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare? Clin Infect Dis, 34, pp. 634-40.
2. Cappelletty, DM and Rybak, MJ. (1996) Comparison of methodologies for synergy testing of drug combinations against resistant strains of Pseudomonas aeruginosa Antimicrob Agents Chemother, 40, pp. 677-83.
3. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th edn: Approved standard M7-A6. NCCLS, VillanovaPA, USA. 2004.
4. Evans, ME and Feola, DJ and Rapp, RP. (1999) Polymyxin B sulfate and colistin: Old antibiotics for emerging multiresistant Gram-negative bacteria Ann Pharmacother, 33, pp. 960-7.
5. Acocella, G. (1978) Clinical pharmacokinetics of rifampicin Clin Pharmacokinet, 3, pp. 108-27.
6. San Gabriel, P and Zhou, J and Tabibi, S and Chen, Y and Trauzzi, M and Saiman, L. (2004) Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis Antimicrob Agents Chemother, 48, pp. 168-71.
7. Bonapace, CR and White, RL and Friedrich, LV and Bosso, JA. (2000) Evaluation of antibiotic synergy against Acinetobacter baumannii: A comparison with E-test, time-kill, and checkerboard methods Diagn Microbiol Infect Dis, 38, pp. 43-50.
8. Tunney, MM and Scott, EM. (2004) Use of breakpoint combination sensitivity testing as a simple and convenient method to evaluate the combined effects of ceftazidime and tobramycin on Pseudomonas aeruginosa and Burkholderia cepacia complex isolates in vitro J Microbiol Methods, 57, pp. 107-14.
9. Saiman, L and Chen, Y and Gabriel, PS and Knirsch, C. (2002) Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis Antimicrob Agents Chemother, 46, pp. 1105-7.
10. Okazaki, M and Suzuki, K and Asano, N and Araki, K and Shukuya, N and Egami, T and (2002) Effectiveness of phosphomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay J Infect Chemother, 8, pp. 37-42.
11. Oie, S and Uematsu, T and Sawa, A and Mizuno, H and Tomita, M and Ishida, S and (2003) In vitro effects of combinations of antipseudomonal agents against 7 strains of multidrug-resistant Pseudomonas aeruginosa J Antimicrob Chemother, 52, pp. 911-4.
12. Erdem, I and Kucukercan, M and Ceran, N. (2003) In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains Chemotherapy, 49, pp. 294-7.
13. Sader, HS and Huynh, HK and Jones, RN. (2003) Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against Gram-negative bacilli Diagn Microbiol Infect Dis, 47, pp. 547-50.
14. Song, W and Woo, HJ and Kim, JS and Lee, KM. (2003) In vitro activity of beta-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa Int J Antimicrob Agents, 21, pp. 8-12.
15. Erdem, I and Kaynar-Tascioglu, J and Kaya, B and Goktas, P. (2002) The comparison of the in vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains Int J Antimicrob Agents, 20, pp. 384-6.
16. Pendland, SL and Messick, CR and Jung, R. (2002) In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa Diagn Microbiol Infect Dis, 42, pp. 75-8.
17. Li, J and Nation, RL and Milne, RW and Turnidge, JD and Coulthard, K. (2005) Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria Int J Antimicrob Agents, 25, pp. 11-25.
18. Beringer, P. (2001) The clinical use of colistin in patients with cystic fibrosis Curr Opin Pulm Med, 7, pp. 434-40.
19. Gunderson, BW and Ibrahim, KH and Hovde, LB and Fromm, TL and Reed, MD and Rotschafer, JC. (2003) Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model Antimicrob Agents Chemother, 47, pp. 905-9.
20. Li, J and Turnidge, J and Milne, R and Nation, RL and Coulthard, K. (2001) In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis Antimicrob Agents Chemother, 45, pp. 781-5.
21. Yoon, J and Urban, C and Terzian, C and Mariano, N and Rahal, JJ. (2004) In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii Antimicrob Agents Chemother, 48, pp. 753-7.
22. Levin, AS and Barone, AA and Penco, J and Santos, MV and Marinho, IS and Arruda, EA and et al. (1999) Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii Clin Infect Dis, 28, pp. 1008-11.
23. Linden, PK and Kusne, S and Coley, K and Fontes, P and Kramer, DJ and Paterson, D. (2003) Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa Clin Infect Dis, 37, pp. 154-60.
24. Sobieszczyk, ME and Furuya, EY and Hay, CM and Pancholi, P and Della-Latta, P and Hammer, SM and et al. (2004) Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections J Antimicrob Chemother, 54, pp. 566-9.
25. Reed, MD and Stern, RC and O'Riordan, MA and Blumer, JL. (2001) The pharmacokinetics of colistin in patients with cystic fibrosis J Clin Pharmacol, 41, pp. 645-54.
26. Ostenson, RC and Fields, BT and Nolan, CM. (1977) Polymyxin B and rifampin: New regimen for multiresistant Serratia marcescens infections Antimicrob Agents Chemother, 12, pp. 655-9.
27. Tascini, C and Menichetti, F and Bozza, S and Del Favero, A and Bistoni, F. (1998) Evaluation of the activities of 2-drug combinations of rifampicin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii J Antimicrob Chemother, 42, pp. 270-1.
28. Giamarellos-Bourboulis, EJ and Sambatakou, H and Galani, I and Giamarellou, H. (2003) In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa J Chemother, 15, pp. 235-8.
29. Tascini, C and Gemignani, G and Ferranti, S and Tagliaferri, E and Leonildi, A and Lucarini, A and et al. (2004) Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections J Chemother, 16, pp. 282-7.